Search Results

The regulator has delayed its respective decision dates on whether to grant full approval to Amgen’s Lumakras in metastatic colorectal cancer and Intercept Pharmaceuticals’ Ocaliva for primary biliary cholangitis.

With a Friday advisory committee meeting looming, the sole indication for Intercept Pharmaceuticals’ Ocaliva appears to be at risk as the regulator flags issues regarding its post-marketing results.

Intercept Pharmaceuticals, Inc. announced nine abstracts related to primary biliary cholangitis and alcohol-related liver disease will be presented at EASL Congress 2024.

Alfasigma S.p.A. (“Alfasigma”) and Intercept Pharmaceuticals, Inc. (“Intercept”) announced today the completion of the acquisition of Intercept by Alfasigma through its wholly owned subsidiary Interstellar Acquisition Inc.

Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, announced five abstracts on primary biliary cholangitis will be presented at Digestive Disease Week® 2024.

Intercept Pharmaceuticals, Inc. is presenting two new sub-analyses from its Phase 3 POISE study in primary biliary cholangitis (PBC), at Digestive Disease Week® (DDW) 2024 in Washington, D.C.

Intercept Pharmaceuticals, Inc. announced new sub-analyses from its Phase 3 POISE trial in primary biliary cholangitis showing the effect of obeticholic acid across a number of key biomarkers of liver health in people living with PBC will be presented at the European Association for the Study of the Liver Congress 2024 being held June 5-8, 2024, in Milan, Italy.

Intercept Pharmaceuticals, Inc. today announced new data from a planned six-month analysis of its ongoing Phase 2 study 747-213 evaluating the combination of obeticholic acid (OCA) and bezafibrate in patients with primary biliary cholangitis (PBC) at the European Association for the Study of the Liver (EASL) Congress 2024 being held June 5-8, 2024, in Milan, Italy.

Intercept Pharmaceuticals, Inc. is presenting new data from a planned six-month analysis of its ongoing Phase 2 study 747-213 evaluating a fixed-dose combination of obeticholic acid and bezafibrate in patients with primary biliary cholangitis at Digestive Disease Week® 2024 in Washington, D.C.